<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);
    }
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 29.2 - Urinary Urge Incontinence (Overactive Bladder)</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 29.2 - Urinary Urge Incontinence | MD3 SCP Cases">
  <meta name="description" content="A 68-year-old woman with sudden urge to urinate and leakage before reaching the toilet. Learn about overactive bladder syndrome, urgency incontinence, antimuscarinics, and β3-agonists.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:url" content="https://md3-scp.netlify.app/cases/case29_2.html">
  <meta property="og:title" content="Case 29.2 - Urinary Urge Incontinence">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="A 68-year-old woman with sudden urge to urinate and leakage before reaching the toilet. Learn about overactive bladder syndrome, urgency incontinence, antimuscarinics, and β3-agonists.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <!-- Twitter -->
  <meta property="twitter:card" content="summary">
  <meta property="twitter:title" content="Case 29.2 - Urinary Urge Incontinence">
  <meta property="twitter:description" content="A 68-year-old woman with sudden urge to urinate and leakage before reaching the toilet. Learn about overactive bladder syndrome, urgency incontinence, antimuscarinics, and β3-agonists.">
  <meta property="twitter:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">

  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 29.2 – Urinary Urge Incontinence (Overactive Bladder)</h1>
    <p class="meta"><strong>Category:</strong> Medicine | <strong>Discipline:</strong> Urogynaecology | <strong>Setting:</strong> General Practice</p>

    <h2>Clinical Scenario</h2>
    <p>Mrs. Margaret Thompson, a 68-year-old woman, presents to her GP with a 6-month history of urinary urgency and incontinence.</p>

    <p><strong>"Doctor, I keep getting these sudden, overwhelming urges to pass urine. I can't hold it - by the time I reach the toilet, I've already wet myself. It's happening 3-4 times a day now. I'm afraid to leave the house in case I have an accident. I'm up 4 times every night to go to the toilet too."</strong></p>

    <h3>History</h3>
    <ul>
      <li><strong>Presenting complaint:</strong> Sudden urge to urinate with inability to hold, leading to leakage before reaching the toilet (6 months, worsening)</li>
      <li><strong>Frequency:</strong> Daytime urinary frequency 12-15 times/day, nocturia 4 times/night</li>
      <li><strong>Character:</strong> Sudden, overwhelming urge with leakage <strong>not related to physical exertion</strong></li>
      <li><strong>Associated symptoms:</strong> No dysuria, no haematuria, no suprapubic pain, no feeling of incomplete emptying</li>
      <li><strong>Obstetric history:</strong> Para 2 (2 normal vaginal deliveries, no complications)</li>
      <li><strong>Gynaecological history:</strong> Menopause age 52, not on HRT</li>
      <li><strong>Past medical history:</strong> Type 2 diabetes (well-controlled, HbA1c 48 mmol/mol), hypertension</li>
      <li><strong>Medications:</strong> Metformin 1g BD, amlodipine 5mg OD</li>
      <li><strong>Social history:</strong> Non-smoker, drinks 6 cups of tea/day, BMI 28</li>
    </ul>

    <h3>Examination</h3>
    <ul>
      <li><strong>Abdominal examination:</strong> Soft, non-tender, no palpable bladder, no masses</li>
      <li><strong>Pelvic examination:</strong>
        <ul>
          <li><strong>Inspection:</strong> Mild vaginal atrophy, no visible prolapse</li>
          <li><strong>Speculum:</strong> No significant prolapse, cervix atrophic (postmenopausal)</li>
          <li><strong>Bimanual:</strong> Small postmenopausal uterus, no adnexal masses</li>
          <li><strong>Cough stress test:</strong> <strong>Negative</strong> - no leakage on coughing</li>
        </ul>
      </li>
      <li><strong>Neurological examination (lower limbs):</strong> Normal power, reflexes, sensation, gait</li>
    </ul>

    <h3>Investigations</h3>
    <ul>
      <li><strong>Urine dipstick:</strong> Glucose ++, no blood, no protein, no leucocytes, no nitrites</li>
      <li><strong>Urine MC&S:</strong> No growth (sterile)</li>
      <li><strong>Bladder diary (3 days):</strong>
        <ul>
          <li>Daytime frequency: 12-15 times</li>
          <li>Nocturia: 4 times/night</li>
          <li>Urgency episodes: 8-10/day</li>
          <li>Incontinence episodes: 3-4/day (all preceded by sudden urge)</li>
          <li>Fluid intake: 2.5L/day (mostly tea)</li>
        </ul>
      </li>
      <li><strong>Post-void residual volume:</strong> 40mL (normal &lt;50mL)</li>
      <li><strong>HbA1c:</strong> 48 mmol/mol (well-controlled diabetes)</li>
    </ul>

    <h2>Questions</h2>

    <div class="question">
      <p><strong>1. What is the diagnosis? Explain the pathophysiology and how you would differentiate this from stress urinary incontinence.</strong></p>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Diagnosis: Overactive Bladder Syndrome (OAB) with Urgency Urinary Incontinence (UUI)</strong></p>

        <p><strong>Definition:</strong></p>
        <ul>
          <li><strong>Overactive bladder syndrome (OAB):</strong> Urinary urgency (sudden compelling desire to pass urine that is difficult to defer) ± urge incontinence, usually with frequency (≥8 times/day) and nocturia (≥2 times/night), in the <strong>absence of UTI or other pathology</strong></li>
          <li><strong>Urgency urinary incontinence (UUI):</strong> Involuntary urine leakage <strong>preceded by urgency</strong></li>
        </ul>

        <p><strong>Classification:</strong></p>
        <ul>
          <li><strong>OAB "dry":</strong> Urgency, frequency, nocturia WITHOUT incontinence (65% of OAB cases)</li>
          <li><strong>OAB "wet":</strong> Urgency, frequency, nocturia WITH urge incontinence (35% of OAB cases - this patient)</li>
        </ul>

        <p><strong>Pathophysiology:</strong></p>
        <p><strong>OAB is caused by detrusor overactivity:</strong> Involuntary contractions of the detrusor muscle during bladder filling → sudden urge to void ± incontinence</p>

        <p><strong>Mechanisms:</strong></p>
        <ul>
          <li><strong>Neurogenic (10-20%):</strong> CNS pathology disrupts normal bladder control
            <ul>
              <li>Examples: Stroke, Parkinson's disease, multiple sclerosis, spinal cord injury</li>
            </ul>
          </li>
          <li><strong>Non-neurogenic/"idiopathic" (80-90%):</strong> No identifiable neurological cause
            <ul>
              <li>Possible mechanisms: Age-related changes, bladder outlet obstruction, bladder hypersensitivity, altered neurotransmitter signalling (acetylcholine)</li>
            </ul>
          </li>
        </ul>

        <p><strong>Differentiation: Urge Incontinence vs Stress Incontinence</strong></p>
        <table>
          <thead>
            <tr>
              <th>Feature</th>
              <th>Urge Incontinence (OAB)</th>
              <th>Stress Incontinence (SUI)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>Trigger</strong></td>
              <td><strong>Sudden urge to void</strong> (no physical exertion needed)</td>
              <td><strong>Physical exertion</strong> (coughing, sneezing, exercise)</td>
            </tr>
            <tr>
              <td><strong>Urgency</strong></td>
              <td><strong>YES - key feature</strong></td>
              <td><strong>NO urgency</strong></td>
            </tr>
            <tr>
              <td><strong>Volume of leakage</strong></td>
              <td>Variable - can be large volume</td>
              <td>Small-to-moderate volume</td>
            </tr>
            <tr>
              <td><strong>Frequency</strong></td>
              <td>Increased (≥8 times/day)</td>
              <td>Normal frequency</td>
            </tr>
            <tr>
              <td><strong>Nocturia</strong></td>
              <td>Common (≥2 times/night)</td>
              <td>Rare</td>
            </tr>
            <tr>
              <td><strong>Cough stress test</strong></td>
              <td><strong>Negative</strong></td>
              <td><strong>Positive</strong> (immediate leakage on coughing)</td>
            </tr>
            <tr>
              <td><strong>Pathophysiology</strong></td>
              <td>Detrusor overactivity</td>
              <td>Pelvic floor weakness ± intrinsic sphincter deficiency</td>
            </tr>
            <tr>
              <td><strong>Typical patient</strong></td>
              <td>Older, neurological disease, diabetes</td>
              <td>Vaginal deliveries, menopause, obesity, chronic cough</td>
            </tr>
          </tbody>
        </table>

        <p><strong>Why This is Urge Incontinence (Not Stress Incontinence):</strong></p>
        <ul>
          <li>✓ Leakage <strong>preceded by sudden, overwhelming urge</strong> (key feature)</li>
          <li>✓ Leakage NOT related to physical exertion</li>
          <li>✓ <strong>Negative cough stress test</strong></li>
          <li>✓ High frequency (12-15 times/day - normal is 4-7 times/day)</li>
          <li>✓ Severe nocturia (4 times/night - normal is 0-1)</li>
          <li>✓ No risk factors for SUI (only 2 normal vaginal deliveries, no forceps/tears)</li>
        </ul>

        <p><strong>Risk Factors Present in This Patient:</strong></p>
        <ul>
          <li><strong>Age (68 years):</strong> OAB prevalence increases with age (affects 30-40% of women >65 years)</li>
          <li><strong>Type 2 diabetes:</strong> Diabetic neuropathy can affect bladder innervation</li>
          <li><strong>High caffeine intake (6 cups tea/day):</strong> Caffeine is a bladder irritant and diuretic</li>
          <li><strong>Postmenopausal:</strong> Oestrogen deficiency → urogenital atrophy → bladder hypersensitivity</li>
        </ul>
      </div>
    </div>

    <div class="question">
      <p><strong>2. Outline a stepwise management plan for this patient, including lifestyle modifications, conservative treatments, and pharmacological options.</strong></p>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Management of Overactive Bladder Syndrome (NICE 2019 Guidelines)</strong></p>

        <p><strong>Step 1: Conservative Management (FIRST-LINE - Trial for 6 Weeks)</strong></p>

        <p><strong>A. Lifestyle Modifications:</strong></p>
        <ul>
          <li><strong>Reduce caffeine intake:</strong> Currently 6 cups tea/day → reduce to ≤2 cups/day
            <ul>
              <li>Caffeine is a bladder irritant and diuretic → worsens urgency/frequency</li>
              <li>Switch to decaffeinated drinks</li>
            </ul>
          </li>
          <li><strong>Reduce evening fluid intake:</strong> Avoid drinking 2-3 hours before bed to reduce nocturia</li>
          <li><strong>Optimize total fluid intake:</strong> Currently 2.5L/day - reduce to 1.5-2L/day (excessive fluids worsen frequency)</li>
          <li><strong>Avoid carbonated drinks and alcohol:</strong> Both are bladder irritants</li>
          <li><strong>Weight loss (if BMI >30):</strong> BMI 28 - encourage healthy weight maintenance</li>
          <li><strong>Treat constipation:</strong> Constipation worsens OAB symptoms</li>
        </ul>

        <p><strong>B. Bladder Training (FIRST-LINE TREATMENT):</strong></p>
        <ul>
          <li><strong>Goal:</strong> Increase bladder capacity, reduce urgency episodes, regain voluntary control</li>
          <li><strong>Programme (supervised by continence nurse/physiotherapist):</strong>
            <ul>
              <li><strong>Education:</strong> Explain normal bladder function, detrusor overactivity, rationale for bladder training</li>
              <li><strong>Scheduled voiding:</strong> Start with comfortable interval (e.g., every 2 hours), gradually increase by 15-30 minutes every 1-2 weeks</li>
              <li><strong>Urge suppression techniques:</strong> When urgency occurs, stop, sit/stand still, distract (count backwards, deep breathing), contract pelvic floor muscles, wait for urge to subside, then walk slowly to toilet</li>
              <li><strong>Avoid "just-in-case" voiding</strong> (voiding before feeling urge) - reinforces abnormal bladder behavior</li>
              <li><strong>Duration:</strong> Minimum 6 weeks (ideally 12 weeks)</li>
            </ul>
          </li>
          <li><strong>Evidence:</strong> 60-80% improvement in urgency/frequency with bladder training</li>
        </ul>

        <p><strong>C. Pelvic Floor Muscle Training (Adjunct):</strong></p>
        <ul>
          <li>PFMT is first-line for SUI but also helps OAB (contracting pelvic floor inhibits detrusor)</li>
          <li>Combine with bladder training for maximum benefit</li>
        </ul>

        <p><strong>D. Optimize Diabetes Control:</strong></p>
        <ul>
          <li>HbA1c 48 mmol/mol (good control) - continue metformin</li>
          <li>Poorly controlled diabetes → polyuria → worsens frequency</li>
        </ul>

        <p><strong>Step 2: Pharmacological Treatment (If Conservative Fails After 6 Weeks)</strong></p>

        <p><strong>A. Antimuscarinics (M3 Receptor Antagonists) - FIRST-LINE MEDICATION:</strong></p>
        <p><strong>Mechanism:</strong> Block muscarinic (M3) receptors on detrusor muscle → reduce involuntary detrusor contractions</p>

        <table>
          <thead>
            <tr>
              <th>Drug</th>
              <th>Dose</th>
              <th>Notes</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>Oxybutynin immediate-release</strong></td>
              <td>2.5-5mg TDS</td>
              <td><strong>Cheapest option</strong> but highest anticholinergic side effects</td>
            </tr>
            <tr>
              <td><strong>Oxybutynin modified-release (MR)</strong></td>
              <td>5-10mg OD</td>
              <td>Fewer side effects than IR formulation</td>
            </tr>
            <tr>
              <td><strong>Tolterodine</strong></td>
              <td>2mg BD or 4mg MR OD</td>
              <td>Lower side effect profile than oxybutynin IR</td>
            </tr>
            <tr>
              <td><strong>Solifenacin</strong></td>
              <td>5-10mg OD</td>
              <td>Once-daily dosing, well-tolerated</td>
            </tr>
          </tbody>
        </table>

        <p><strong>Antimuscarinic Side Effects (Anticholinergic Effects):</strong></p>
        <ul>
          <li><strong>Common:</strong> Dry mouth (most common - 30%), constipation, blurred vision</li>
          <li><strong>Serious:</strong> Urinary retention (especially in elderly men), cognitive impairment (confusion, memory problems - particularly in elderly)</li>
          <li><strong>WARNING in elderly (this patient is 68):</strong> Antimuscarinics associated with increased dementia risk (MHRA warning) - use lowest effective dose, review regularly</li>
        </ul>

        <p><strong>Contraindications to Antimuscarinics:</strong></p>
        <ul>
          <li>Closed-angle glaucoma, myasthenia gravis, urinary retention, severe constipation, gastric retention</li>
          <li><strong>Caution in elderly:</strong> Risk of cognitive impairment, falls</li>
        </ul>

        <p><strong>B. β3-Adrenergic Agonist (Alternative to Antimuscarinics):</strong></p>
        <ul>
          <li><strong>Mirabegron 25-50mg OD</strong></li>
          <li><strong>Mechanism:</strong> Stimulates β3-adrenoceptors on detrusor muscle → bladder relaxation during filling</li>
          <li><strong>Advantages:</strong> NO anticholinergic side effects (no dry mouth, no cognitive impairment) - <strong>preferred in elderly patients</strong></li>
          <li><strong>Side effects:</strong> Hypertension (monitor BP), tachycardia, headache, UTI</li>
          <li><strong>Contraindications:</strong> Severe uncontrolled hypertension (BP >180/110) - <strong>caution in this patient (has hypertension)</strong></li>
          <li><strong>Cost:</strong> More expensive than antimuscarinics (may not be first-line due to cost)</li>
        </ul>

        <p><strong>C. Vaginal Oestrogen (Adjunct in Postmenopausal Women):</strong></p>
        <ul>
          <li>Does not directly treat OAB but improves urogenital atrophy → may reduce bladder hypersensitivity</li>
          <li>Safe in this patient (no contraindications)</li>
        </ul>

        <p><strong>Step 3: Specialist Interventions (If Medications Fail)</strong></p>

        <p><strong>Indications for Urogynaecology Referral:</strong></p>
        <ul>
          <li>Failure of conservative + 2 different antimuscarinic trials</li>
          <li>Haematuria (exclude malignancy)</li>
          <li>Recurrent UTIs</li>
          <li>Suspected neurological cause</li>
          <li>Pelvic organ prolapse</li>
        </ul>

        <p><strong>Specialist Treatment Options:</strong></p>
        <ul>
          <li><strong>A. Botulinum Toxin A (Botox) Injections into Detrusor:</strong>
            <ul>
              <li>Mechanism: Blocks acetylcholine release → paralysis of detrusor muscle</li>
              <li>Efficacy: 60-70% improvement, lasts 6-12 months (requires repeat injections)</li>
              <li>Risk: Urinary retention (5-10%) - may require clean intermittent self-catheterization (CISC)</li>
            </ul>
          </li>
          <li><strong>B. Percutaneous Tibial Nerve Stimulation (PTNS):</strong>
            <ul>
              <li>Weekly 30-minute sessions (12 weeks) - needle inserted near tibial nerve → neuromodulation of bladder control</li>
              <li>Efficacy: 50-60% improvement, non-invasive</li>
            </ul>
          </li>
          <li><strong>C. Sacral Neuromodulation (SNM):</strong>
            <ul>
              <li>Implantable device (pacemaker-like) that stimulates sacral nerves (S3) → modulates bladder control</li>
              <li>Efficacy: 70-80% improvement</li>
              <li>Invasive, expensive, reserved for refractory cases</li>
            </ul>
          </li>
        </ul>

        <p><strong>Management Plan for This Patient:</strong></p>
        <ol>
          <li><strong>Immediate:</strong>
            <ul>
              <li>Refer to continence nurse/women's health physiotherapist for <strong>bladder training</strong> (6-week programme)</li>
              <li><strong>Lifestyle advice:</strong> Reduce caffeine to ≤2 cups/day, reduce evening fluids, aim 1.5-2L total/day</li>
              <li>Prescribe <strong>vaginal oestrogen</strong> (e.g., Ovestin cream) for vaginal atrophy</li>
            </ul>
          </li>
          <li><strong>Review in 6 weeks:</strong> If inadequate response → start pharmacological treatment:
            <ul>
              <li><strong>First choice (given age 68, cognitive risk):</strong> <strong>Mirabegron 25mg OD</strong> (no anticholinergic effects) - but check BP first (has hypertension)</li>
              <li><strong>Alternative:</strong> Oxybutynin MR 5mg OD or Solifenacin 5mg OD (lower anticholinergic burden than oxybutynin IR)</li>
            </ul>
          </li>
          <li><strong>Review in 4 weeks after starting medication:</strong> Assess efficacy + side effects, titrate dose if needed</li>
          <li><strong>If 2 medication trials fail:</strong> Refer to urogynaecology for specialist interventions (Botox, PTNS, SNM)</li>
        </ol>
      </div>
    </div>

    <h2>Key Learning Points</h2>
    <div class="key-points">
      <ul>
        <li><strong>Overactive bladder syndrome (OAB)</strong> = urinary urgency (sudden compelling desire to void) ± urge incontinence, usually with frequency (≥8/day) and nocturia (≥2/night), in the absence of UTI/pathology</li>
        <li><strong>Urgency urinary incontinence (UUI)</strong> = involuntary leakage <strong>preceded by urgency</strong> - caused by detrusor overactivity (involuntary detrusor contractions)</li>
        <li><strong>Differentiate from stress incontinence:</strong> UUI = leakage preceded by sudden urge (no exertion), SUI = leakage with physical exertion (no urgency)</li>
        <li><strong>Risk factors for OAB:</strong> Age, neurological disease (stroke, Parkinson's, MS), diabetes, high caffeine intake, menopause</li>
        <li><strong>First-line treatment: Bladder training (6 weeks)</strong> + lifestyle modifications (reduce caffeine, optimize fluids) - 60-80% improvement</li>
        <li><strong>Pharmacological options:</strong>
          <ul>
            <li><strong>Antimuscarinics (oxybutynin, tolterodine, solifenacin):</strong> Block M3 receptors → reduce detrusor contractions</li>
            <li><strong>Side effects:</strong> Dry mouth (30%), constipation, cognitive impairment (especially elderly) - MHRA warning re: dementia risk</li>
            <li><strong>β3-agonist (mirabegron):</strong> NO anticholinergic effects - preferred in elderly, but monitor BP (can cause hypertension)</li>
          </ul>
        </li>
        <li><strong>Vaginal oestrogen:</strong> Adjunct in postmenopausal women (improves urogenital atrophy)</li>
        <li><strong>Specialist interventions (if medications fail):</strong> Botox injections (60-70% success, risk urinary retention), percutaneous tibial nerve stimulation (PTNS), sacral neuromodulation (SNM)</li>
        <li><strong>Red flags requiring urgent referral:</strong> Haematuria (exclude malignancy), recurrent UTIs, suspected neurological cause, pelvic mass</li>
      </ul>
    </div>

  </div>

  <!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/dark-mode.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/user-analytics.js"></script>
  <script src="../js/analytics-integration.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        
    }
      
    }
    
    }
// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      
    }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      
    }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          
    }
        }, 100);
      
    }
    });
    
    }
  </script>

</body>
</html>
